About Caribou Biosciences, Inc.
Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
2BBBullish & Bearish
Caribou Biosciences, Inc. (CRBU) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 15 out of 100.
Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
Caribou Biosciences, Inc.’s current 2BB score is 15 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 3 | Very Low |
| Momentum | 32 | Weakening |
| Financial strength | 9 | Very Weak |
| Company Presence | 55 | Normal |
| Risk | 49 | Moderate (provisional) |
| Headquarters | Berkeley, California, United States |
| Founded | Jan 1, 2011 |
| Employees | 97 |
| 52-week range | $0.44 – $3.53 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-03-01 | — | -0.1955 | — | $2.96M |
| 2026-11-05 | -0.25 | -0.2756 | $1.61M | $1.65M |
| 2026-08-13 | — | -0.3232 | — | $2.32M |
| 2026-05-07 | -0.26 | -0.3242 | $2.40M | $2.29M |